19 results about "Paliperidone" patented technology

The invention relates to the technical field of paliperidone metabolic efficiency evaluation, in particular to a paliperidone metabolic efficiency evaluation system based on a CYP2D6 gene and environmental factors. According to the system, the obtained historical data information is preprocessed, so that more effective data information can be obtained, and a model can be trained more effectively by using the data information; meanwhile, a dynamic metabolism prediction module formed by weighting output of each network in a multi-modal feature fusion module by utilizing a gating attention mechanism is trained based on the preprocessed data, so that a gene-environment-PK / PD multi-dimensional model is obtained, various factors of the environment and the gene can be quantified, and multi-modal data are fused; the dynamic evaluation of the metabolic efficiency is further realized; according to the method, the current data information is scored by using the gene-environment-PK / PD multi-dimensional model, and the score is compared with the preset score, so that whether the model evaluation is qualified or not can be quickly judged, and the model evaluation is adjusted when the model evaluation is unqualified, thereby further improving the evaluation accuracy.

The present application relates to the field of medical informatics, and provides a paliperidone efficacy prediction method and system based on plasma metabolomics. The method comprises the following steps: collecting basic data of a target patient; performing feature selection on metabolites through the basic data to obtain relevant metabolites corresponding to paliperidone efficacy; training a neural network based on the relevant metabolites and baseline data in the basic data to obtain a prediction model; and performing paliperidone efficacy prediction on a patient to be predicted through the prediction model to obtain a prediction result. The present application can predict the probability of patient response to paliperidone, thereby more accurately evaluating the efficacy of paliperidone before medication, and providing an auxiliary decision for individualized medication.

The present invention provides a method of treating a patient with a long-acting injectable paliperidone palmitate formulation.

The present invention provides a paliperidone cocrystal, and a preparation method therefor and a use thereof. The cocrystal former of the paliperidone cocrystal is nicotinic acid. The paliperidone cocrystal is obtained by dissolving paliperidone and nicotinic acid in an aqueous organic solvent and then evaporating to dryness under reduced pressure. The paliperidone cocrystal of the present invention has high purity and stable quality, is suitable for commercial storage, has greatly improved solubility and dissolution rate, and is more suitable for the development of paliperidone preparations.

The present application relates to the field of medical informatics, and provide a paliperidone efficacy prediction method and system based on plasma proteomics, the method comprises the following steps: collecting the basic data of the target patient; selecting the protein features through the basic data to obtain the related proteins corresponding to the paliperidone efficacy; training the neural network based on the related proteins and the baseline data in the basic data to obtain the prediction model; predicting the paliperidone efficacy of the patient to be predicted through the prediction model to obtain the prediction result. The present application can predict the treatment response of schizophrenic patients to paliperidone, and significantly improve the objectivity of paliperidone use.

This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.

The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).

1. Name of the product in this design: Pharmaceutical Packaging Box (Pariporone Extended-Release Tablets). 2. Purpose of this design: Packaging box for paliperidone sustained-release tablets. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the key design points: Design 1 3D view. 5. The design for which protection is sought includes color. 6. Design 1 is designated as the basic design.

To provide a method for treating a psychotic patient in need of treatment with a long-acting injectable paliperidone palmitate formulation.SOLUTION: A method for administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of a first paliperidone palmitate extended release injectable suspension (first suspension), the method comprising: Administering a resumption loading dose of a second paliperidone palmitate extended release injectable suspension (second suspension) to the patient's deltoid muscle at a time point that is greater than 6 months and less than 3 weeks after administration of the first dose of the first suspension, and administering a maintenance dose of the first suspension to the patient's deltoid muscle or gluteus maximus muscle at a time point that is about 1 month (+ / -7 days) after administration of the resumption loading dose of the second suspension.SELECTED DRAWING: None

The invention relates to a paliperidone co-crystal and a preparation method thereof, and the method comprises the following steps: dissolving paliperidone and nicotinic acid in a water-containing organic solvent, and drying by distillation under reduced pressure to obtain the paliperidone co-crystal. The obtained crystal is high in purity, stable in quality and suitable for commercial storage, the solubility and the dissolution rate are greatly improved, and the crystal is more suitable for development of paliperidone solid preparations.

The present application relates to the technical field of colorectal cancer treatment, in particular to a kind of paliperidone in preparation colorectal cancer drug, paliperidone and PD-1 antibody combined use in preparation colorectal cancer drug application.The present application is based on virtual screening and molecular docking technology, using FDA approved anticancer drug library identifies the drug Paritaprevir (paliperidone) capable of directly targeting PLS3, and provides Paritaprevir combined with PD-1 targeted antibody treatment regimen, optimizes the dilemma that the effect of PD-1 targeted antibody monotherapy is not ideal, so that more colorectal cancer patients benefit.

The invention provides a paliperidone dosage optimization method and device, electronic equipment and a storage medium, and belongs to the technical field of artificial intelligence, and the method comprises the steps: obtaining the state data of a patient, the state data comprising the plasma concentration of paliperidone, the heart rate variability (HRV) time domain index and the smoking amount; preprocessing the state data to obtain preprocessed state data, and performing feature extraction on the preprocessed state data to obtain a feature vector of the blood concentration, a feature vector of the HRV time domain index and a feature vector of the smoking amount; and inputting the feature vector of the blood concentration, the feature vector of the HRV time domain index and the feature vector of the smoking amount into a pre-constructed dose optimization model to obtain the optimal dose of paliperidone of the patient output by the dose optimization model. According to the method, the optimal dose of the paliperidone of the patient is predicted based on the dose optimization model, so that the accuracy of dose prediction is improved, a personalized treatment scheme is convenient to formulate, and the curative effect of the medicine is improved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a paliperidone long-acting oral suspension based on ion exchange resin and a preparation method of the paliperidone long-acting oral suspension. The cation exchange resin and the paliperidone are adopted to form a medicine-resin compound, pH responsive release is achieved through ionic bonds, and the effects of low dissociation in gastric juice and slow release in intestinal juice are achieved; meanwhile, a ready-to-use oral suspension is developed for patients with dysphagia, a flavoring agent is added, the taste is improved, compared with controlled release tablets, the compliance of the patients can be improved, the medication convenience can be improved, and the paliperidone long-acting oral suspension preparation has a good application prospect.

The invention provides a paliperidone sustained release tablet and a preparation method thereof, and relates to the technical field of pharmaceutical preparations, the paliperidone sustained release tablet comprises the following raw materials by weight: 3-6 parts of paliperidone, 30-50 parts of medium chain triglyceride, 25-40 parts of polysorbate, 10-30 parts of hydroxypropyl methylcellulose, 5-30 parts of ethyl cellulose, 10-20 parts of silica, 1-2 parts of magnesium stearate and 3 parts of a gastric soluble film coating premix; the method comprises the five steps of self-emulsifying liquid preparation, solid dispersion adsorption, sustained-release skeleton granulation, mixing and tabletting and sustained-release coating, stable release of paliperidone is successfully achieved through cooperation of double mechanisms of self-emulsifying solubilization and skeleton sustained release, meanwhile, the prescription and the process are simplified, the production difficulty and cost are reduced, and the product quality is improved. The paliperidone sustained-release preparation has remarkable clinical application value and wide industrial potential, and a more economical, efficient and sustainable solution is provided for the paliperidone sustained-release preparation.

The invention discloses a paliperidone coated tablet. The paliperidone coated tablet comprises a tablet core layer and a shell layer, the tablet core layer comprises the following components in parts by weight: 5-10 parts of paliperidone, 1-2 parts of a plasticizer, 0.1-0.5 part of a flow aid, 10-30 parts of a carrier, 22-28 parts of a retardant A, 40-70 parts of a sustained-release material A and 0.1-0.5 part of a lubricant A, wherein the sum of the parts of the raw materials is 100; the shell layer comprises the following components in parts by weight: 0.5-0.8 part of paliperidone, 250-260 parts of a sustained-release material B, 60-70 parts of a retardant B and 1-2 parts of a lubricant B, and the sum of the parts by weight of the raw materials is 320. The composition is simple in components, convenient to use, simple in preparation process and controllable in cost.

The invention relates to a method for detecting related substances in paliperidone, in particular to a method for simultaneously detecting eight known impurities in paliperidone by adopting a high performance liquid chromatography, the method can realize effective separation and determination of the eight known impurities in paliperidone, the separation degree is high, the system durability is strong, and the method is suitable for industrial production. The method is simple in operation, high in detection sensitivity and accuracy, capable of ensuring controllable quality of paliperidone raw material medicines and preparations, simple to operate and suitable for industrial application.

To provide a method for treating a psychotic patient in need of treatment with a long-acting injectable paliperidone palmitate formulation.SOLUTION: A method for administering paliperidone palmitate to a patient in need thereof who has been administered a first dose of paliperidone palmitate sustained release injectable suspension, comprising administering a second dose of the paliperidone palmitate sustained release injectable suspension to the deltoid or gluteal muscle of the patient up to two weeks before or three weeks after a time point that is six months after administration of the first dose, wherein there are no intervening doses of paliperidone palmitate between the first dose and the second dose.SELECTED DRAWING: None

The present invention provides a method of treating a patient with a long-acting injectable paliperidone palmitate formulation.

The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.